Connection
Joshua Petit to Prostatic Neoplasms
This is a "connection" page, showing publications Joshua Petit has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.464 |
|
|
|
-
Petit JH, Gluck C, Kiger WS, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol. 2008 Jul-Aug; 26(4):372-7.
Score: 0.160
-
Petit JH, Gluck C, Kiger WS, Laury Henry D, Karasiewicz C, Talcott JA, Berg S, Holupka EJ, Kaplan ID. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy. 2007 Oct-Dec; 6(4):267-71.
Score: 0.157
-
Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D'Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer. 2006 Nov 01; 107(9):2180-5.
Score: 0.147